サンプル依頼リスト カート
  • English
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1729537

日本の経口抗糖尿病薬市場レポート：薬剤別、地域別、2025年～2033年

Japan Oral Anti-Diabetic Drug Market Report by Drug (Biguanides, Alpha-Glucosidase Inhibitors, Dopamine D2 Receptor Agonist, SGLT-2 inhibitors, DPP-4 inhibitors, Sulfonylureas, Meglitinides), and Region 2025-2033

出版日
発行
IMARC
ページ情報
英文 121 Pages
納期
5～7営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=151.79円
日本の経口抗糖尿病薬市場レポート：薬剤別、地域別、2025年～2033年
出版日: 2025年05月01日
発行: IMARC
ページ情報: 英文 121 Pages
納期: 5～7営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

日本の経口抗糖尿病薬の市場規模は2024年に24億米ドルに達しました。今後、IMARC Groupは、市場は2033年までに37億米ドルに達し、2025～2033年の成長率（CAGR）は4.42％になると予測しています。ライフスタイルの変化や肥満率の増加などの要因による糖尿病有病率の上昇が、主に市場成長の原動力となっています。

本レポートで扱う主な質問

  • 日本の経口抗糖尿病薬市場はこれまでどのように推移し、今後どのように推移するのか？
  • COVID-19が日本の経口抗糖尿病薬市場に与えた影響は？
  • 日本の経口抗糖尿病薬市場の薬剤別区分は？
  • 日本の経口抗糖尿病薬市場のバリューチェーンにおけるさまざまな段階とは？
  • 日本の経口抗糖尿病薬の主な促進要因と課題は何か？
  • 日本の経口抗糖尿病薬市場の構造と主要プレーヤーは？
  • 日本の経口抗糖尿病薬市場における競合の程度は？

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査の目的
  • ステークホルダー
  • データソース
  • 市場推定
  • 調査手法

第3章 エグゼクティブサマリー

第4章 日本の経口抗糖尿病薬市場：イントロダクション

  • 概要
  • 市場力学
  • 業界動向
  • 競合情報

第5章 日本の経口抗糖尿病薬市場情勢

  • 過去および現在の市場動向（2019～2024年）
  • 市場予測（2025～2033年）

第6章 日本の経口抗糖尿病薬市場：薬剤別

  • ビグアナイド
  • アルファグルコシダーゼ阻害剤
  • ドーパミンD2受容体作動薬
  • SGLT-2阻害剤
  • DPP-4阻害剤
  • スルホニル尿素
  • メグリチニド

第7章 日本の経口抗糖尿病薬市場：競合情勢

  • 概要
  • 市場構造
  • 市場企業のポジショニング
  • 主要成功戦略
  • 競合ダッシュボード
  • 企業評価象限

第8章 主要企業のプロファイル

第9章 日本の経口抗糖尿病薬市場：業界分析

  • 促進要因、抑制要因、機会
  • ポーターのファイブフォース分析
  • バリューチェーン分析

第10章 付録

目次
Product Code: SR112025A15652

Japan oral anti-diabetic drug market size reached USD 2.4 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 3.7 Billion by 2033, exhibiting a growth rate (CAGR) of 4.42% during 2025-2033. The rising prevalence of diabetes, due to factors like changing lifestyles and the increasing obesity rates, is primarily driving the market growth.

Oral anti-diabetic drugs, pivotal in the management of type 2 diabetes, are pharmacological agents designed to regulate blood glucose levels in individuals whose bodies either resist the effects of insulin or don't produce enough. While insulin injections remain a primary treatment for diabetes, oral antidiabetic medications offer a non-invasive alternative and often serve as the first line of defense against the progression of the disease. These medications operate through various mechanisms, such as stimulating the pancreas to produce more insulin, reducing the liver's glucose production, or improving insulin sensitivity in body tissues.

Japan Oral Anti-Diabetic Drug Market Trends:

Japan's oral antidiabetic drug market is a critical segment of its healthcare industry, reflecting both the nation's advanced medical research capabilities and its demographic challenges. With an aging population and increasing urbanization, there's been a notable rise in lifestyle diseases, including type 2 diabetes. A distinctive driver in the regional market is the strong emphasis on research and development activities. The approval of innovative drug classes, such as DPP-4 inhibitors and SGLT2 inhibitors, has not only expanded treatment options but also offered improved glycemic control with reduced side effects. Another trend shaping the market is the growing inclination towards personalized medicine. Recognizing that diabetes manifests differently in individuals, there's a push towards tailoring treatments based on genetic, environmental, and lifestyle factors. Consequently, combination therapies, which use two or more antidiabetic drugs, are gaining traction to achieve better blood sugar control. Furthermore, the Japanese government's proactive stance on healthcare, with policies promoting regular health check-ups and early detection, indirectly boosts the oral antidiabetic drug market. By emphasizing preventive measures and timely intervention, the country not only addresses the immediate health needs but also mitigates long-term healthcare costs associated with diabetes-related complications. Apart from this, the introduction of treatment modalities is anticipated to propel the market growth over the forecasted period.

Japan Oral Anti-Diabetic Drug Market Segmentation:

Drugs Insights:

  • Biguanides
    • Metformin
  • Alpha-Glucosidase Inhibitors
  • Dopamine D2 Receptor Agonist
    • Bromocriptin
  • SGLT-2 inhibitors
    • Invokana (Canagliflozin)
    • Jardiance (Empagliflozin)
    • Farxiga/Forxiga (Dapagliflozin)
    • Suglat (Ipragliflozin)
  • DPP-4 inhibitors
    • Onglyza (Saxagliptin)
    • Tradjenta (Linagliptin)
    • Vipidia/Nesina (Alogliptin)
    • Galvus (Vildagliptin)
  • Sulfonylureas
  • Meglitinides

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

Key Questions Answered in This Report:

  • How has the Japan oral anti-diabetic drug market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the Japan oral anti-diabetic drug market?
  • What is the breakup of the Japan oral anti-diabetic drug market on the basis of drugs?
  • What are the various stages in the value chain of the Japan oral anti-diabetic drug market?
  • What are the key driving factors and challenges in the Japan oral anti-diabetic drug?
  • What is the structure of the Japan oral anti-diabetic drug market and who are the key players?
  • What is the degree of competition in the Japan oral anti-diabetic drug market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Japan Oral Anti-Diabetic Drug Market - Introduction

  • 4.1 Overview
  • 4.2 Market Dynamics
  • 4.3 Industry Trends
  • 4.4 Competitive Intelligence

5 Japan Oral Anti-Diabetic Drug Market Landscape

  • 5.1 Historical and Current Market Trends (2019-2024)
  • 5.2 Market Forecast (2025-2033)

6 Japan Oral Anti-Diabetic Drug Market - Breakup by Drugs

  • 6.1 Biguanides
    • 6.1.1 Overview
    • 6.1.2 Historical and Current Market Trends (2019-2024)
    • 6.1.3 Market Segmentation
      • 6.1.3.1 Metformin
    • 6.1.4 Market Forecast (2025-2033)
  • 6.2 Alpha-Glucosidase Inhibitors
    • 6.2.1 Overview
    • 6.2.2 Historical and Current Market Trends (2019-2024)
    • 6.2.3 Market Forecast (2025-2033)
  • 6.3 Dopamine D2 Receptor Agonist
    • 6.3.1 Overview
    • 6.3.2 Historical and Current Market Trends (2019-2024)
    • 6.3.3 Market Segmentation
      • 6.3.3.1 Bromocriptin
    • 6.3.4 Market Forecast (2025-2033)
  • 6.4 SGLT-2 inhibitors
    • 6.4.1 Overview
    • 6.4.2 Historical and Current Market Trends (2019-2024)
    • 6.4.3 Market Segmentation
      • 6.4.3.1 Invokana (Canagliflozin)
      • 6.4.3.2 Jardiance (Empagliflozin)
      • 6.4.3.3 Farxiga/Forxiga (Dapagliflozin)
      • 6.4.3.4 Suglat (Ipragliflozin)
    • 6.4.4 Market Forecast (2025-2033)
  • 6.5 DPP-4 inhibitors
    • 6.5.1 Overview
    • 6.5.2 Historical and Current Market Trends (2019-2024)
    • 6.5.3 Market Segmentation
      • 6.5.3.1 Onglyza (Saxagliptin)
      • 6.5.3.2 Tradjenta (Linagliptin)
      • 6.5.3.3 Vipidia/Nesina(Alogliptin)
      • 6.5.3.4 Galvus (Vildagliptin)
    • 6.5.4 Market Forecast (2025-2033)
  • 6.6 Sulfonylureas
    • 6.6.1 Overview
    • 6.6.2 Historical and Current Market Trends (2019-2024)
    • 6.6.3 Market Forecast (2025-2033)
  • 6.7 Meglitinides
    • 6.7.1 Overview
    • 6.7.2 Historical and Current Market Trends (2019-2024)
    • 6.7.3 Market Forecast (2025-2033)

7 Japan Oral Anti-Diabetic Drug Market - Competitive Landscape

  • 7.1 Overview
  • 7.2 Market Structure
  • 7.3 Market Player Positioning
  • 7.4 Top Winning Strategies
  • 7.5 Competitive Dashboard
  • 7.6 Company Evaluation Quadrant

8 Profiles of Key Players

  • 8.1 Company A
    • 8.1.1 Business Overview
    • 8.1.2 Product Portfolio
    • 8.1.3 Business Strategies
    • 8.1.4 SWOT Analysis
    • 8.1.5 Major News and Events
  • 8.2 Company B
    • 8.2.1 Business Overview
    • 8.2.2 Product Portfolio
    • 8.2.3 Business Strategies
    • 8.2.4 SWOT Analysis
    • 8.2.5 Major News and Events
  • 8.3 Company C
    • 8.3.1 Business Overview
    • 8.3.2 Product Portfolio
    • 8.3.3 Business Strategies
    • 8.3.4 SWOT Analysis
    • 8.3.5 Major News and Events
  • 8.4 Company D
    • 8.4.1 Business Overview
    • 8.4.2 Product Portfolio
    • 8.4.3 Business Strategies
    • 8.4.4 SWOT Analysis
    • 8.4.5 Major News and Events
  • 8.5 Company E
    • 8.5.1 Business Overview
    • 8.5.2 Product Portfolio
    • 8.5.3 Business Strategies
    • 8.5.4 SWOT Analysis
    • 8.5.5 Major News and Events

9 Japan Oral Anti-Diabetic Drug Market - Industry Analysis

  • 9.1 Drivers, Restraints and Opportunities
    • 9.1.1 Overview
    • 9.1.2 Drivers
    • 9.1.3 Restraints
    • 9.1.4 Opportunities
  • 9.2 Porters Five Forces Analysis
    • 9.2.1 Overview
    • 9.2.2 Bargaining Power of Buyers
    • 9.2.3 Bargaining Power of Suppliers
    • 9.2.4 Degree of Competition
    • 9.2.5 Threat of New Entrants
    • 9.2.6 Threat of Substitutes
  • 9.3 Value Chain Analysis

10 Appendix